H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, is in talks with several potential partners to help develop a treatment for Alzheimer’s disease, Chief Executive Officer Ulf Wiinberg said. The company, which released results from a mid-stage study on the AE58054 drug in May, will start late-stage trials as early as the end of 2012, Wiinberg said today. Pfizer Inc. (PFE) and Johnson & Johnson’s announcement this week that they were ending development of their failed bapineuzumab Alzheimer’s drug may benefit Copenhagen-based Lundbeck.
